Adult Malignant Glioma Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Adult Malignant Glioma Therapeutics Market has been Segmented by Type of Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, and Other Types of Diseas), Therapy (Chemotherapy, Targeted Drug Therapy, and Radiation Therapy) and Geography.

Market Snapshot

adult malignant glioma therapeutics market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 9.6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The development of a promising drug to treat malignant glioma has proved difficult to date, with many promising candidates failing to achieve the desired test results in the past few years. 

However, technological advancements in the diagnosis of gliomas and analysis of its progression, through various imaging modalities, have improved survival rates, thereby giving an enhanced edge for rapid evaluation of the efficacy of several pipeline drugs. 

North America and Europe are projected to dominate the global adult malignant glioma therapeutics market during the forecast period, primarily due to the significant reimbursement coverage. The market in the Asia Pacific is expected to expand at a significant CAGR between 2020-2025.

According to the World Health Organization, globally, an estimated 245,000 cases of brain and nervous system tumors are reported each year. Glioblastoma multiforme is the most common and the most lethal of these tumors. Gliomas are categorized under rare diseases; however, the incidence rate across the globe has witnessed a steady rise in the last decade. Adoption of novel drug discovery technologies, such as high-throughput screening and TCGA, has reduced the overall drug discovery time and the cost of drug development. This is attributed to a rising number of players participating in new product development and launches in various therapy areas, including glioma.

Scope of the Report

Malignant brain tumors strike deep into the psyche of those receiving and those delivering the diagnosis. Malignant gliomas, the most common subtype of primary brain tumors, are aggressive, highly invasive, and neurologically destructive tumors, considered to be among the deadliest of human cancers.

Type of Disease
Glioblastoma Multiforme
Anaplastic Astrocytoma
Anaplastic Oligodendroglioma
Anaplastic Oligoastrocytoma
Other Types of Disease
Therapy
Chemotherapy
Temozolomide
Bevacizumab
Carmustine
Other Types of Chemotherapy
Targeted Drug Therapy
Epidermal Growth Factor Receptor (EGFR) Inhibitors
Other Monoclonal Antibodies
Radiation Therapy
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Glioblastoma Multiforme Segment is Expected to Exhibit the Fastest Growth over the Forecast Period

In terms of type, the global adult malignant glioma therapeutics market has been classified into glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. According to the Case Reports in Oncology, 2018, around 200 cases were reported worldwide for glioblastoma multiforme. Consequently, this segment is likely to be the most attractive segment during the forecast period, followed by anaplastic astrocytoma. Intense research and development focus of manufacturers, the presence of significant patient population driving demand for effective therapeutics to improve the overall survival rate, and rapidly increasing the pipeline of innovative novel drugs are attributed to the high growth of the segment.

Malignant Glioma Therapeutics Market Trend Image.png

North America Holds the Largest Market Share

North America is expected to dominate the global market , owing to technological advancement in the adult malignant glioma therapuetics. However, growth of the market in the near future is likely to depend on the combined prospects in technology and opportunity in the developing countries in Asia, such as China, Japan, India, and South Korea. The market in Asia-Pacific is anticipated to register an above average growth rate during the forecast period, owing to a relatively high patient population demanding affordable care and improvements in healthcare infrastructure to aid in the early diagnosis of malignant gliomas.

Adult Malignant Glioma Therapeutics Market - Growth Rate by Region

Competitive Landscape

The leading vendors of the market are expanding their operations in Asian countries (India, China, Japan, and South Korea)m as these economies hold immense potential for glioma products, given the increasing prevalence of neural disorders in the region. The major players operating in the market include Merck & Co. Inc., F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories, among others.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Incurable Status of the Disease

      2. 4.2.2 Global Increase in Aging Population

      3. 4.2.3 Increasing Prevalence of Brain Disorders

    3. 4.3 Market Restraints

      1. 4.3.1 Diminishing Preference for Chemotherapy

      2. 4.3.2 Low Approval Rates for Novel Therapeutics for Glioma

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Type of Disease

      1. 5.1.1 Glioblastoma Multiforme

      2. 5.1.2 Anaplastic Astrocytoma

      3. 5.1.3 Anaplastic Oligodendroglioma

      4. 5.1.4 Anaplastic Oligoastrocytoma

      5. 5.1.5 Other Types of Disease

    2. 5.2 Therapy

      1. 5.2.1 Chemotherapy

        1. 5.2.1.1 Temozolomide

        2. 5.2.1.2 Bevacizumab

        3. 5.2.1.3 Carmustine

        4. 5.2.1.4 Other Types of Chemotherapy

      2. 5.2.2 Targeted Drug Therapy

        1. 5.2.2.1 Epidermal Growth Factor Receptor (EGFR) Inhibitors

        2. 5.2.2.2 Other Monoclonal Antibodies

      3. 5.2.3 Radiation Therapy

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AbbVie, Inc.

      2. 6.1.2 Amgen, Inc.

      3. 6.1.3 Arbor Pharmaceuticals

      4. 6.1.4 Bio Rad Laboratories

      5. 6.1.5 Bristol-Myers Squibb Company

      6. 6.1.6 F. Hoffmann-La Roche Ltd

      7. 6.1.7 Pfizer, Inc.

      8. 6.1.8 Sun Pharmaceuticals Ltd

      9. 6.1.9 Merck & Co. Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Adult Malignant Glioma Therapeutics Market market is studied from 2018 - 2026.

The Adult Malignant Glioma Therapeutics Market is growing at a CAGR of 9.6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Merck & Co. Inc., F. Hoffmann-La Roche Ltd, Arbour Pharmaceuticals LLC, Bristol-Myers Squibb Company, Bio-Rad Laboratories are the major companies operating in Adult Malignant Glioma Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!